Join us for the 2nd BIO-Europe in Cologne, Germany, November 9–11, 2026, the premier biopharma partnering event now transformed into a comprehensive forum for biotech leaders.
Spanish biotech Minoryx Therapeutics has secured a positive European regulatory opinion for Nezglyal, two years after regulators rejected an earlier application for the rare neurodegenerative disease drug.
https://european-biotechnology.com/wp-content/uploads/2026/07/egor-myznik-lbbGlDBN0PA-unsplash-scaled.jpg17042560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-24 15:45:312026-07-24 15:45:31CHMP backs Minoryx’s rare disease drug two years after rejection
Sanofi has ended the development of amlitelimab in atopic dermatitis and will not seek regulatory approval for the drug, concluding that it would not meaningfully improve on existing treatments.
Newly formed Synaptiq Therapeutics has acquired substantially all the assets of Nobias Therapeutics, including a clinical-stage drug whose development has already spanned several companies and more than three decades.
German healthcare group Fresenius has created a corporate venture capital unit that plans to invest more than €200 million in healthcare startups over the next five years.
Swiss biotech Neurimmune has sold part of its future royalties from its AstraZeneca-partnered experimental heart drug cliramitug to Royalty Pharma for up to $425 million, giving it fresh cash to invest in its remaining antibody pipeline.
Berlin-based OMEICOS Therapeutics can move OMT-28 directly into a pivotal Phase 3 trial in primary mitochondrial diseases after receiving supportive feedback from the U.S. Food and Drug Administration (FDA).
Novartis has discontinued development of Lu-NeoB, an experimental radioligand therapy targeting the gastrin-releasing peptide receptor, after early clinical data failed to support further development.
Swiss biotech Immitra Bio has raised CHF 2.4 million (€2.6 million) in pre-seed funding to advance an in-vivo gene editing platform initially targeting inherited blood disorders.
U.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. The focus is on extrachromosomal DNA rings.
https://european-biotechnology.com/wp-content/uploads/2026/07/team-phinomics-bayer-colab2026.jpg540960Georg Kääb/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngGeorg Kääb2026-07-21 13:47:372026-07-21 13:47:37Phinomics Brings a New Layer of Cancer Biology from the U.S. to Berlin
BIO-Europe 2026
Sponsored PublicationsJoin us for the 2nd BIO-Europe in Cologne, Germany, November 9–11, 2026, the premier biopharma partnering event now transformed into a comprehensive forum for biotech leaders.
CHMP backs Minoryx’s rare disease drug two years after rejection
Latest NewsSpanish biotech Minoryx Therapeutics has secured a positive European regulatory opinion for Nezglyal, two years after regulators rejected an earlier application for the rare neurodegenerative disease drug.
Sanofi drops eczema drug from $1.1B Kymab deal
Latest NewsSanofi has ended the development of amlitelimab in atopic dermatitis and will not seek regulatory approval for the drug, concluding that it would not meaningfully improve on existing treatments.
Iceland-based Synaptiq launches with Nobias’ rare disease drug
Latest NewsNewly formed Synaptiq Therapeutics has acquired substantially all the assets of Nobias Therapeutics, including a clinical-stage drug whose development has already spanned several companies and more than three decades.
Fresenius launches €200M healthcare venture fund
Latest NewsGerman healthcare group Fresenius has created a corporate venture capital unit that plans to invest more than €200 million in healthcare startups over the next five years.
Neurimmune turns future royalties into $425m pipeline cash
Latest NewsSwiss biotech Neurimmune has sold part of its future royalties from its AstraZeneca-partnered experimental heart drug cliramitug to Royalty Pharma for up to $425 million, giving it fresh cash to invest in its remaining antibody pipeline.
OMEICOS takes repurposed drug directly into Phase 3
Latest NewsBerlin-based OMEICOS Therapeutics can move OMT-28 directly into a pivotal Phase 3 trial in primary mitochondrial diseases after receiving supportive feedback from the U.S. Food and Drug Administration (FDA).
Novartis drops Phase 2 radioligand therapy
Latest NewsNovartis has discontinued development of Lu-NeoB, an experimental radioligand therapy targeting the gastrin-releasing peptide receptor, after early clinical data failed to support further development.
Immitra Bio raises CHF 2.4M for in-vivo gene editing
Latest NewsSwiss biotech Immitra Bio has raised CHF 2.4 million (€2.6 million) in pre-seed funding to advance an in-vivo gene editing platform initially targeting inherited blood disorders.
Phinomics Brings a New Layer of Cancer Biology from the U.S. to Berlin
Latest NewsU.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. The focus is on extrachromosomal DNA rings.